TCR2 Therapeutics
675 West Kendall Street
Suite I
Cambridge
Massachusetts
02142
United States
Tel: 617-475-8469
Website: http://www.tcr2.com/
Email: info@tcr2.com
About TCR2 Therapeutics
At TCR2 Therapeutics we have a bold vision – to cure cancer by using our immune system in a more natural way. We have developed a unique proprietary TRuC™ platform based on T cell receptor fusion constructs that have the advantage of employing the full signaling power inherent to a complete T cell receptor (TCR). Our TRuC™ variants can reprogram the natural TCR complex to recognize specific antigens found on tumors where they elicit rapid killing of cancer cells. We have demonstrated activity against both hematological and solid tumor targets in preclinical models and we believe TRuC™-T cells will serve as the engine for novel therapies which we are quickly advancing towards the clinic.The company was founded in 2015 by Dr. Patrick Baeuerle and backed with a $44.5M Series A financing led by MPM Capital and F2 Ventures. We have since assembled a world class team of immunotherapy experts and entrepreneurs located in the heart of Kendall Square in Cambridge, MA.
YEAR FOUNDED:
2015
LEADERSHIP:
Founder: Dr. Patrick Baeuerle
CEO: Garry Menzel, PhD and MBA
CSO: Robert Hofmeister, PhD
Acting CSO: John Pallies
Chief IP Counsel: Gregory Sieczkiewicz, PhD and JD
Head of Corporate Development: Helen Ho, PhD
Manager of Human Reources & Office Dynamics: Eva Quinn
TECHNOLOGY:
Please click here for TCR2 Therapeutics's technology.
112 articles with TCR2 Therapeutics
-
TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023
2/8/2023
TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will present a company update at the SVB Securities Global Biopharma Conference (virtual) on Tuesday, February 14, 2023 at 1:00 PM ET.
-
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 05, 2023
1/5/2023
TCR2 Therapeutics Inc. announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 9,600 shares of TCR2’s common stock to 3 new non-executive employees.
-
TCR² Therapeutics Announces Pipeline Priorities for 2023
1/5/2023
TCR2 Therapeutics Inc. today announced its pipeline priorities for 2023 as it concentrates resources on completing the ovarian cancer cohort in the Phase 2 clinical trial of gavo-cel and accelerating the development of its second-generation enhanced TRuC T-cell therapy programs, TC-510 and TC-520.
-
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 01, 2022
12/1/2022
TCR2 Therapeutics Inc., a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 24,400 shares of TCR2’s common stock to 3 new non-executive employees.
-
TCR² Therapeutics to Present at the Piper Sandler Healthcare Conference
11/23/2022
TCR 2 Therapeutics Inc. today announced that management will participate in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference on Tuesday, November 29 at 2:00PM E.T.
-
TCR² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
11/8/2022
TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced financial results for the third quarter ended September 30, 2022 and provided a corporate update.
-
TCR² Therapeutics Presents Preclinical Data on Functional Activity of Gavo-cel at the Society for Immunotherapy of Cancer
11/7/2022
TCR2 Therapeutics Inc. announced the poster presentation of new preclinical data at the Society for Immunotherapy of Cancer Conference 37th Annual Meeting, taking place November 8-12, 2022.
-
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 01, 2022
11/1/2022
TCR2 Therapeutics Inc. announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 2,600 shares of TCR2’s common stock to 1 new non-executive employees.
-
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 03, 2022
10/3/2022
TCR2 Therapeutics Inc., a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 19,400 shares of TCR2’s common stock to 1 new non-executive employees.
-
TCR2 Therapeutics announced promising Phase I data for gavo-cel in mesothelin-expression that points toward effects in multiple solid tumors, especially ovarian cancer.
-
TCR² Therapeutics to Announce Complete Phase 1 Portion of the Gavo-cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid Tumors
9/27/2022
TCR 2 Therapeutics Inc. today announced that the Company plans to discuss the complete Phase 1 portion of the gavo-cel Phase 1/2 clinical trial for mesothelin-expressing solid tumors in a premarket press release and conference call to be held on Wednesday, September 28th, 2022 at 8:00am E.T.
-
TCR² Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
9/26/2022
TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will participate in a fireside chat at the Jefferies Cell & Genetic Medicine Summit on Thursday, September 29 at 2:00PM E.T.
-
TCR2 Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 01, 2022
9/1/2022
Therapeutics Inc. announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 7,600 shares of TCR2’s common stock to 2 new non-executive employees.
-
TCR² Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8/8/2022
TCR2 Therapeutics Inc., a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, announced financial results for the second quarter ended June 30, 2022 and provided a corporate update.
-
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
8/1/2022
TCR 2 Therapeutics Inc. today announced the Compensation Committee of the Board of Directors of TCR 2 approved the grant of inducement stock options covering an aggregate of 46,600 shares of TCR 2 ’s common stock to 2 new non-executive employees.
-
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 01, 2022
7/1/2022
TCR2 Therapeutics Inc. announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 250,000 shares of TCR2’s common stock to 1 new executive employee on June 27, 2022 and an aggregate of 64,800 shares of TCR2’s common stock to 9 new non-executive employees on June 30, 2022.
-
Entering the second half of 2022, biopharma and life sciences companies from across the globe strengthen their leadership teams with new additions to the c-suite.
-
TCR² Therapeutics Appoints Industry and Finance Veteran Eric Sullivan as Chief Financial Officer
6/27/2022
TCR2 Therapeutics Inc. announced the appointment of Eric Sullivan as Chief Financial Officer where he will be responsible for leading all aspects of financial management and capital market strategy as well as overseeing investor relations and select business operations.
-
TCR² Therapeutics to Participate in Two Upcoming Conferences in June 2022
6/1/2022
TCR2 Therapeutics Inc. announced that management will participate at two upcoming conferences in June in New York.
-
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 01, 2022
6/1/2022
TCR2 Therapeutics Inc. announced that on May 31, 2022, the Compensation Committee of the Board of Directors of TCR2’s approved the grant of inducement stock options covering an aggregate of 19,800 shares of TCR2’s common stock to 3 new non-executive employees.